Skip to main content

Search This Blog

Pulmonary Hypertension

Posts

4 Sleep Problems Related to Heart Failure, and How to Manage Them

Get link
Facebook
X
Pinterest
Email
Other Apps

November 11, 2026

Invalid Access Key! Invalid Access Key!

Afib and Low Blood Pressure: What’s the Connection?

Get link
Facebook
X
Pinterest
Email
Other Apps

November 11, 2026

Invalid Access Key! Invalid Access Key!

Hypertension: Background, Etiology, Pathophysiology

Get link
Facebook
X
Pinterest
Email
Other Apps

November 11, 2026

Invalid Access Key! Invalid Access Key!

Precision medicine and personalized nursing in cardiovascular disease: clinical applications and frontier developments

Get link
Facebook
X
Pinterest
Email
Other Apps

November 09, 2026

Invalid Access Key! Invalid Access Key!

Abstract - 2026 - Pediatric Pulmonology

Get link
Facebook
X
Pinterest
Email
Other Apps

November 09, 2026

Invalid Access Key! Invalid Access Key!

Radiofrequency catheter ablation for pulmonary hypertension patients with atrial flutter

Get link
Facebook
X
Pinterest
Email
Other Apps

November 08, 2026

Invalid Access Key! Invalid Access Key!

Abstract - 2026 - Pediatric Pulmonology

Get link
Facebook
X
Pinterest
Email
Other Apps

November 08, 2026

Invalid Access Key! Invalid Access Key!

Powered by Blogger

Theme images by 4x6

Archive

November19
October33
September59
August59
July47
June22
May41
April32
March70
February59

Show more Show less

Popular posts from this blog

Ambrisentan/Tadalafil FDC Bioequivalent to Monotherapies in Healthy Individuals - Pulmonology Advisor

Ambrisentan/Tadalafil FDC Bioequivalent to Monotherapies in Healthy Individuals - Pulmonology Advisor Ambrisentan/Tadalafil FDC Bioequivalent to Monotherapies in Healthy Individuals - Pulmonology Advisor Posted: 04 Jun 2019 12:00 AM PDT In both fed and fasted healthy volunteers, an ambrisentan and tadalafil fixed-dose combination (FDC) is bioequivalent to concurrently administered monotherapies, with tolerability and safety consistent with the individual monotherapies, according to a study published in Clinical Therapeutics . Combination therapy with ambrisentan and tadalafil has been shown to be more effective for the prevention of clinical failure events in patients with pulmonary arterial hypertension than either drug alone. The aim of this randomized, 3-part, single-dose, open-label, 5-way crossover study was to evaluate the bioequivalence of 4 FDC formulations of ambrisentan and tadalafil compared with the coadministration of the 2 m...

Pulmonary Hypertension in Myelofibrosis: Risks and Treatments - www.oncnursingnews.com/

Pulmonary Hypertension in Myelofibrosis: Risks and Treatments - www.oncnursingnews.com/ Pulmonary Hypertension in Myelofibrosis: Risks and Treatments - www.oncnursingnews.com/ 4 Pulmonary Hypertension Programs Receive PHA's PHCC Accreditation - Benzinga Aria Raises $31M for Planned Study of Balloon Implant to Treat PAH - Pulmonary Hypertension News Pulmonary Hypertension in Myelofibrosis: Risks and Treatments - www.oncnursingnews.com/ Posted: 19 Mar 2020 08:53 AM PDT There may be certain factors that put a patient with myelofibrosis at a higher risk for pulmonary hypertension, according to Juan C. Lopez-Mattei, MD, FACC, FASE, FSCCT, FSCMR. Lopez-Mattei, a multimodality imaging cardiologist and associate professor of cardiology and diagnostic imaging at The University of Texas MD Anderson Cancer Center, was the lead author of an analysis that examined 143 patients with myelofibrosis who received an echocardiograp...

In SSc, Cardiopulmonary Exercise Test May Help Detect PAH, Study Says - Scleroderma News

December 18, 2019

In SSc, Cardiopulmonary Exercise Test May Help Detect PAH, Study Says - Scleroderma News In SSc, Cardiopulmonary Exercise Test May Help Detect PAH, Study Says - Scleroderma News Posted: 27 Nov 2019 12:00 AM PST Cardiopulmonary exercise testing (CPET), along with an algorithm that considers both lung and heart functions, can help lower the unnecessary use of right heart catheterization to determine if a scleroderma patient has pulmonary arterial hypertension , a study reports. The study, " Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis ," appeared in the journal Rheumatology . Pulmonary arterial hypertension (PAH) — a frequent and severe complication of scleroderma (SSc) — is characterized by thickening of connective tissue which narrows small arteries in the lung. This narrowing, in turn, increases pressure within pulmonary blood vessels. ...

Labels

"pulmonary hypertension prognosis" - Google News
idiopathic pulmonary hypertension
IFTTT
mild pulmonary hypertension
pulmonary artery hypertension
Pulmonary Hypertension
pulmonary hypertension causes
pulmonary hypertension diagnosis
pulmonary hypertension medications
pulmonary hypertension prognosis

pulmonary hypertension symptoms
pulmonary hypertension treatment
severe pulmonary hypertension
what is pulmonary hypertension

Show more Show less

yand